Australian therapeutic antibody development company Patrys (ASX:PAB) has announced results from a recently completed pre-clinical study that it says validates the potential to use its full-size IgG deoxymab, PATDX3, for synthetic lethality strategies to treat relevant cancers.
Patrys' says preclinical data supports synthetic lethality mechanism
March 15, 2023 Australian Biotech
Latest Video
New Stories
-
Medicines Australia backs focus on listings and productivity in government brief
July 3, 2025 - - Latest News -
AusBiotech seeking a head of investment to drive sector growth
July 3, 2025 - - Australian Biotech -
What's the point of pretending that Australia doesn't free-ride on US innovation?
July 3, 2025 - - Latest News -
Framework pushes genomics funding to a review that is mostly silent on it
July 3, 2025 - - Latest News -
Draft 'National Health Genomics Policy Framework' out for consultation
July 3, 2025 - - Latest News -
MedAdvisor announces agreement confirming the sale of Australian business
July 3, 2025 - - Latest News -
GBMA announces planned departure of long-standing CEO
July 2, 2025 - - Latest News